634 results about "Steroid" patented technology

Disclosed are methods of treating a subject having clinically significant signs and symptoms associated with blood cell differentiation and treated with an agent that reduces the level and / or activity of BRG1 and / or BRM. The methods disclosed herein may include, e.g., administering to the subject an effective amount of a corticosteroid, hydroxyurea, or furosemide, or subjecting the subject to leukapheresis.

The invention discloses a high-stability hydroxysteroid dehydrogenase mutant, a co-immobilized enzyme construction method and application. According to the invention, a site-directed mutant library is constructed based on computer-aided design, and mutants with significantly improved thermal stability and greatly improved catalytic efficiency compared with wild type mutants are obtained through screening; meanwhile, a co-immobilized enzyme construction method based on electrostatic adsorption and chemical crosslinking is established, the hydroxysteroid dehydrogenase mutant and lactic dehydrogenase are co-immobilized, the co-immobilized enzyme can still keep high activity under high substrate concentration, and the conversion rate is still maintained to be 90% or above after 30 batches of co-immobilized enzyme are repeatedly used. And an important foundation is laid for industrial application of the hydroxysteroid dehydrogenase.

The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.

The invention belongs to the technical field of biological medicine, and discloses a novel adjuvant recombinant herpes zoster vaccine and a preparation method thereof. The vaccine is composed of gE-gD protein and a liposome adjuvant, the liposome adjuvant is prepared by the following steps: co-dissolving 3D-MLA, phospholipid-containing components and steroid components in an organic solvent to form a film, hydrating and homogenizing with PBS, finally adding QS-21, and fixing the volume with PBS. According to the process, enhanced components are uniformly and stably anchored in a membrane phase micro-domain, and the particle structure is controllable. Under the same antigen dosage and detection caliber, the D28 GMC of the vaccine is obviously improved, and more sufficient and stronger primary humoral immune response is embodied.

This invention relates to a crystalline 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I),and compositions thereof. Also disclosed herein are methods of making the same and methods of using the same.

In some aspects, the present disclosure provides compositions of lipid nanoparticles useful for the delivery of large RNAs including mRNAs. These compositions may include a cationic ionizable lipid, a phospholipid, a PEGylated lipid, and a steroid including using less of a cationic ionizable lipid than compositions with shorter nucleic acids. These compositions may be used to treat a disease or disorder for which the delivery of an mRNA is therapeutically effective.

The invention provides an application of a pentacyclic triterpenoid compound targeting hydroxyl steroid 17-beta dehydrogenase 4. The pentacyclic triterpenoid compound can effectively relieve or treat central nervous system diseases (inflammatory diseases), including central nervous system degenerative diseases or chronic central inflammatory diseases. The pentacyclic triterpenoid compound can maintain the structural stability or activity of hydroxysteroid 17-beta dehydrogenase and maintain the stability or activity of peroxisome, thereby relieving or treating central nervous inflammation. The pentacyclic triterpenoid compound can target hydroxysteroid 17-beta dehydrogenase 4, inhibit neuroglial cell excessive activation related neuroinflammation, relieve neuron damage or death speed and improve a central nervous system cell metabolism microenvironment.

The invention provides a breeding method for constructing XX / XY sex determination all-female sterile fish and application. The method comprises the following steps: knocking out a catalytic enzyme coding gene of a fish sex steroid hormone synthesis pathway by using a gene editing technology to block the fish sex steroid hormone synthesis pathway, screening to obtain an effectively mutated homozygote XX sex genetic type pseudo male fish, and hybridizing the pseudo male fish with improved allotetraploid crucian and carp female fish to obtain the fish sex steroid hormone synthesis pathway. Therefore, an allotriploid population is obtained, and the population completely develops into female fishes and is sterile, so that the effect of obtaining all-female and sterile populations is achieved at the same time. The method provided by the invention has very strong applicability, and can be widely applied to aquaculture of fishes to obtain female unisexual groups of the fishes so as to improve the aquaculture yield, realize effective control on female fertility and protect ecological safety; the method has a wide application prospect in the fields of genetic breeding and ecological safety of aquaculture fishes.

The present disclosure provides methods of treating inflammation of the upper gastrointestinal tract, especially the esophagus, by administering an oral corticosteroid. In some cases, the methods include treating eosinophilic esophagitis (EoE) by administering an oral corticosteroid in an induction phase and a maintenance phase to improve peak eosinophilic counts and symptoms. In embodiments, the methods include treating EoE by administering the oral corticosteroid at nighttime and / or while the patient is lying down.

The invention discloses a progesterone 5beta-reductase mutant and application thereof in synthesis of 5beta-dihydrosteroid, relates to the technical field of biology, and in particular relates to application of gene mining and engineering modification of progesterone 5beta-reductase derived from bacteria in asymmetric synthesis of 5beta-dihydrosteroid. According to the progesterone 5 beta-reductase LpP5beta R disclosed by the invention, the progesterone 5 beta-reductase LpP5beta R from bacteria psoromais is obtained by a gene mining method, and the progesterone 5 beta-reductase LpP5beta R can be subjected to soluble expression in escherichia coli. The mutant obtained by mutating the wild type LpP5beta R has obviously improved catalytic ability on progesterone, and can efficiently catalyze delta 4-3-carbonyl steroids such as hydrocortisone, dinorcitol and the like to generate corresponding 5beta-dihydrosteroids. According to the invention, the technical bottlenecks of poor heterologous expression and low catalytic efficiency of plant-derived progesterone 5beta-reductase are solved, and a potential biocatalyst is provided for green manufacturing of 5beta-dihydrosteroid drugs.

The invention relates to the technical field of medical detection, in particular to a method for detecting aldosterone, cortisol, deoxycorticosterone and cortisone in plasma through LC-MS / MS. The method comprises the following steps: (a) mixing a plasma sample with an internal standard solution to obtain a mixed solution; (b) adding the mixed solution into the magnetic bead suspension, sequentially carrying out adsorption, weak washing, strong washing and elution, and collecting an eluent; (c) carrying out liquid nitrogen blowing and redissolving on the eluent, and then carrying out LC-MS / MS detection; wherein the surfaces of the magnetic beads are modified with steroid adsorption groups, and the target detection objects are aldosterone, cortisol, deoxycorticosterone and cortisone. The detection method is convenient and simple, the detection efficiency is higher than that of a traditional method, and a feasible solution is provided for promoting popularization and application of the LC-MS / MS technology in clinical practice.

A method is disclosed for the treatment of human subjects diagnosed with immune thrombocytopenia (ITP). The method comprises administering to a human subject a human neonatal Fc receptor (hFcRn) antagonist, optionally in combination with standard-of-care ITP treatment. In certain embodiments, the hFcRn antagonist is efgartigimod (ARGX-113). Standard-of-care ITP treatment may comprise administration of corticosteroids, immunosuppressants, and / or thrombopoietin receptor (TPO-R) agonists.

The present invention is directed to orally administered corticosteroid compositions. The present invention also provides a method for treating a condition associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention.

The present disclosure relates to methods of treating major depressive disorder (MDD) or postpartum depression (PPD) in a subject in need thereof with a combination of Compound (1) and an additional antidepressant, followed by continued administration of the additional antidepressant.

The present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a drug which is prone to oxidation, said method comprising the addition of an additive to prevent oxidation of the drug which is prone to oxidation. In particular, the present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a corticosteroid, said method comprising the addition of an additive to prevent oxidation of the corticosteroid. The present disclosure also relates to a composition comprising a corticosteroid and an additive to prevent oxidation of the corticosteroid.

Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I):and pharmaceutically acceptable salts thereof; wherein , R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a drug which is prone to oxidation, said method comprising the addition of an additive to prevent oxidation of the drug which is prone to oxidation. In particular, the present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a corticosteroid, said method comprising the addition of an additive to prevent oxidation of the corticosteroid. The present disclosure also relates to a composition comprising a corticosteroid and an additive to prevent oxidation of the corticosteroid.

The invention belongs to the field of biological medicine, and particularly relates to an organic molecule self-assembly serving as a material-free medicine carrying system and a preparation method and application thereof. The invention provides a self-assembly body, the self-assembly body is composed of steroid series molecules, and a material-free drug loading system formed by self-assembly of the steroid series molecules is prepared by optimizing the molecular structure and critical aggregation concentration of the steroids. The material-free drug loading system can be used for loading drugs and preparing drug nano-composites. In the nano compound, the drug effect of the drug is improved, and the effects of reducing toxicity and improving efficiency can be achieved. Furthermore, if the used steroid molecules have biological activity, the pharmacological activity of the steroid molecules is not influenced after the steroid molecules are prepared into the drug nano-composite. The material-free drug loading system prepared by the invention has the advantages of no carrier and two nano preparations taking the traditional material as the carrier, and has a good prospect in the aspect of developing novel nano drug preparations.

Provided are methods for treating pemphigus using an FcRn antagonist such as efgartigimod. The methods of the invention provide a rapid onset of action to enable early disease control and maintenance of clinical remission, with or without a minimal dose of corticosteroids.

The present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a drug which is prone to oxidation, said method comprising the addition of an additive to prevent oxidation of the drug which is prone to oxidation. In particular, the present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a corticosteroid, said method comprising the addition of an additive to prevent oxidation of the corticosteroid. The present disclosure also relates to a composition comprising a corticosteroid and an additive to prevent oxidation of the corticosteroid.

The present disclosure provides compositions that exhibit preferential targeting or delivery of nucleic acid compositions to specific organs. In some embodiments, the compositions comprise steroids or sterols, ionizable cationic lipids, phospholipids, PEG lipids, and permanent cationic lipids, which can be used to deliver nucleic acids. The invention also provides the use of the composition in the preparation of a medicament for targeted delivery of a therapeutic agent to an organ or cells in an organ.

The invention provides a functional peptide with a yang tonifying effect, a seal penis peptide and a preparation method and application of the functional peptide and the seal penis peptide. The functional peptide comprises a peptide fragment pER and can promote testicular interstitial cells to secrete testosterone. Testosterone is steroid hormone and can be secreted by testicular interstitial cells through enzymatic reaction. The low testosterone level in serum can cause male testicular atrophy and low sperm survival rate, so that the male reproductive function is influenced, and the phenomena of poor sexual desire, premature ejaculation, erectile dysfunction and the like can also be caused. In addition, the testosterone also has the effects of maintaining muscle strength and quality, maintaining bone density and strength, refreshing, improving physical ability and the like. Therefore, the functional peptide provided by the invention has the effect of promoting the secretion of testosterone, which means that the functional peptide not only can effectively improve the male sexual function, but also can alleviate the damage of male sexual dysfunction to the body and spirit.

The present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a drug which is prone to oxidation, said method comprising the addition of an additive to prevent oxidation of the drug which is prone to oxidation. In particular, the present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a corticosteroid, said method comprising the addition of an additive to prevent oxidation of the corticosteroid. The present disclosure also relates to a composition comprising a corticosteroid and an additive to prevent oxidation of the corticosteroid.

The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.

The invention discloses a steroid hormone degrading bacterium as well as a screening method and application thereof, and relates to the field of biological medicines, the steroid hormone degrading bacterium comprises klebsiella pneumoniae (KP2022 Klebsiella pneumoniae) with the preservation number of CCTCC (China Center for Type Culture Collection) NO: M2025478. The steroid hormone degrading bacterium provided by the invention has the capability of efficiently degrading dexamethasone, is beneficial to degrading dexamethasone in the environment, is conveniently obtained by adopting a screening method, and provides a sample for research on degradation of steroid hormones.

The present invention provides an amino lipid, and lipid nanoparticles (LNPs) and a use thereof, the amino lipid having a structure represented by general formula (I), or an isomer, pharmaceutically acceptable salt, prodrug or solvate of the amino lipid. The present invention further provides LNPs containing the amino lipid. According to the present invention, the amino lipid having a structure represented by general formula (I) is used as an ionizable lipid compound, and the LNPs are obtained by means of self-assembly of the ionizable lipid compound, a steroid, a neutral lipid, and a polymer-bonded lipid. The LNPs can further improve the translation expression level of a nucleic acid load in cells, improve the effect of a nucleic acid-LNP preparation, and enable the nucleic acid-LNP preparation to provide a theoretical basis for personalized treatment.

The invention discloses lipid nanoparticles targeting liver cells as well as a preparation method and application of the lipid nanoparticles. Raw materials of the lipid nanoparticles comprise lipid targeting dirty cells, and the lipid targeting dirty cells is selected from at least one of galactosyl lipid, N-acetyl galactosamino lipid, lactosyl lipid, mannose-based lipid, glycolipid, glycerol glycolipid, steroid glycolipid, glycerol cholic acid lipid or N-alkenyl lipid. The low-toxicity lipid nanoparticle for efficiently targeting the liver is high in delivery efficiency, has remarkable liver targeting, low immunogenicity and excellent biocompatibility, and is applicable to delivery of various drugs, gene therapy and vaccines needing liver targeting delivery.

The present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a drug which is prone to oxidation, said method comprising the addition of an additive to prevent oxidation of the drug which is prone to oxidation. In particular, the present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a corticosteroid, said method comprising the addition of an additive to prevent oxidation of the corticosteroid. The present disclosure also relates to a composition comprising a corticosteroid and an additive to prevent oxidation of the corticosteroid.

The present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a drug which is prone to oxidation, said method comprising the addition of an additive to prevent oxidation of the drug which is prone to oxidation. In particular, the present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a corticosteroid, said method comprising the addition of an additive to prevent oxidation of the corticosteroid. The present disclosure also relates to a composition comprising a corticosteroid and an additive to prevent oxidation of the corticosteroid.

The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.